About this program
This program aims at developing an anti-CD39 antibody for immuno-oncology. By targeting the adenosine immunosuppressive pathway, it has the potential to promote anti-tumor immune responses across a wide range of tumors.
CD39 is a membrane-bound extracellular enzyme overexpressed on both regulatory T cells and several cancer types. It plays a major role in promoting immunosuppression through the pathway degrading adenosine triphosphate (ATP) into adenosine. Within the tumor microenvironment, ATP promotes immune cell-mediated killing of cancer cells. In contrast, adenosine accumulation causes immune suppression and dysregulation of immune cell infiltrates resulting in tumor spreading. Blockade of CD39 may therefore stimulate anti-tumor immunity across a wide range of tumors (including kidney, lung, ovarian, pancreatic, thyroid, testicular, endometrial, and prostate tumors, as well as in lymphoma and melanoma) by preventing the production of immunosuppressive adenosine and by promoting the accumulation of ATP in the tumor microenvironment.
Innate Pharma has selected the lead candidate, IPH5201, a CD39-blocking antibody aiming at restoring a pro-inflammatory microenvironment, currently in preclinical development.
Mechanism of action of IPH5201 (anti-CD39)
Ivan Perrot et al, 2019. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies Cell Reports Bastid et al, 2015. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity Cancer Immunol Res. Bastid et al, 2013. CD39 is a promising therapeutic target in oncology Oncogene